Spectrum Pharmaceuticals and Zevalin: The Importance of FDA Approval

Jul. 19, 2009 2:09 PM ET, , , 8 Comments
Justin M. Hall
1.17K Followers

Investors should find the resources in this article helpful to their research efforts on Spectrum Pharmaceuticals regarding Zevalin.

As of March 16, 2009, Zevalin is now manufactured and sold in the US by Spectrum Pharmaceuticals (Nasdaq: SPPI). Zevalin is currently approved as a last resort treatment for refractory NHL. SPPI is seeking approval for Zevalin as a first-line consolidation therapy for NHL. A FDA decision on Zevalin is expected by September 8, 2009.

ZEVALIN’S APPROVAL IS IMPORTANT FOR PATIENTS WITH NHL.

If Zevalin is approved under the first-line consolidation setting, the drug is more likely to have a better shot at becoming the standard of care for NHL. Some patients, who have received Zevalin or a comparable radioimmunotherapeutic (RIT), Bexxar, would likely argue that Zevalin deserves to be approved and made available for early-stage patients. The current standard of care is Rituxan in combination with chemotherapy. Rituxan is marketed by partners Roche (OTCQX:RHHBY) and Biogen Idec (Nasdaq: BIIB). Bexxar is marketed by GlaxoSmithKline (NYSE: GSK).

BETSY DE PARRY

Betsy de Parry’s story is one with a happy ending. Betsy is a NHL survivor, one of a few patients in the US who has actually received a RIT for the treatment of her NHL. While Betsy’s story ended positively, more importantly, it exemplifies why patients should be made aware of the Zevalin option. Please make it a point to check out Betsy’s site. Investors should consider purchasing her book, The Roller Coaster Chronicles, which is available for sale on her site.

MUST SEE VIDEO ON ZEVALIN

Video: Zevalin and Bexxar

OTHER RESOURCES

New York Times article July, 14 2007 which also features Betsy de Parry as well as other NHL survivors.

On July 16, 2007, a blogger responds to the July 14 New York Times article, infra. Here, I found Betsy de

This article was written by

1.17K Followers
Justin M. Hall is an extremely accomplished independent financial analyst with more than a decade of experience in the financial markets. He consistently provides expertise to a variety of financial clients and is known for his successful market predictions. Between 2010 and 2014 Justin made 239 specific market recommendations via his online subscription service with an 80% accuracy rate. He has produced enduring results for a variety of clients including those who trade stocks, invest their own money, desire personal wealth management, and institutional investors. But more than an analyst, Justin is a person who influences and persuades, whose judgement is well respected and highly trusted, and whose opinion is sought by those searching for financial and investment advice. Justin received his undergraduate degree from Indiana State University and attended law school at Indiana University. His desire to serve the financial and investment needs of individual clients led him to start Rx Investors.com, an online subscription service that connected individual investors with his expert analysis. Subscribers from all over the world utilized Justin’s advice to generate market income and grow their individual portfolios. Many of these subscribers and clients continued to seek Justin’s analysis and advice for many years, appreciating his unique perspective on the financial industry. A variety of financial outlets have recognized Justin’s expertise and highlighted his work including the Orange County Business Journal, Seeking Alpha, and Zack’s Investment Research. These industry connections have allowed Justin to lend his expert advice to others and expand his influence.

Recommended For You

Related Stocks

SymbolLast Price% Chg
ASRT--
Assertio Holdings, Inc.
BIIB--
Biogen Inc.
RHHBY--
Roche Holding AG
GSK--
GSK plc

Related Analysis